William Mack, MD
Ophthalmic Plastic and Reconstructive Surgery · Tampa, FLNPI 1679570816
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,398 of the $4,988 with a category attached, or 88.2%. 12 manufacturers reported payments, led by Merz North America, Inc. at 25.5% of the total. Reporting peaked in 2019 at $1,413 and has fallen 57.6% since, to $599 in 2025.
Across 72 payments — averaging $69.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$1K
- AbbVie$1K
- Galderma Laboratories, L.p.$1K
- Amgen$735
- Revance Therapeutics, Inc.$235
- Alcon$195
- plus $410 from 6 others
What the payments were for
- Consulting fees$1403%
- Speaking & faculty fees$4509%
- Food & beverage$4,39888%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 15 | $1,270 |
| AbbVie(2 entities) | 28 | $1,109 |
| Galderma Laboratories, L.p. | 5 | $1,034 |
| Amgen(2 entities) | 14 | $735 |
| Revance Therapeutics, Inc. | 2 | $235 |
| Alcon | 2 | $195 |
| Medtronic | 1 | $140 |
| Glaukos Corporation | 1 | $100 |
| LKC Technologies, Inc. | 1 | $80 |
| Endo Pharmaceuticals Inc. | 1 | $42 |
| Dompe US, Inc. | 1 | $27 |
| Baxter Healthcare | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,988 in reported general payments places this provider in the 75th percentile of 37 ophthalmic plastic and reconstructive surgery providers in Florida.
See all ophthalmic plastic and reconstructive surgery providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 292 | $2,853 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 32 | $1,392 |
| ErythromycinErythromycin Base | 32 | $336 |
| Methylprednisolone | 33 | $200 |
| Cephalexin | 13 | $106 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Tampa
- Adam ScheinerTampa$3K
- Jay OlderTampa$638
- John FezzaVenice$3.6M
- Wendy LeeMiami$616K
- Jennifer MurdockMiami$316K
- Ana VictoriaMiami$130K
- Keshini ParbhuWindermere$102K
- Sara WesterMiami$78K
- Robert ApplebaumLakeland$39K
- Yasaman MohadjerSt Petersburg$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.